Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion
Ming-He Huang, Yewen Wu, Vincent Nguyen, Saurabh Rastogi, Bradley K McConnell, Cori Wijaya, Barry F Uretsky, Kian-Keong Poh, Huay-Cheem Tan, Kenichi Fujise, Ming-He Huang, Yewen Wu, Vincent Nguyen, Saurabh Rastogi, Bradley K McConnell, Cori Wijaya, Barry F Uretsky, Kian-Keong Poh, Huay-Cheem Tan, Kenichi Fujise
Abstract
Introduction: The present study determined whether late-ischemia/early reperfusion therapy with the β(1)-adrenergic receptor (AR) blocker esmolol and phosphodiesterase III inhibitor milrinone reduced left ventricular (LV) myocardial infarct size (IS).
Methods and results: In an ischemia/reperfusion rat model (30-min ischemia/4-hr reperfusion), esmolol, milrinone or esmolol + milrinone were intravenous (IV) infused over 10 min (from the last 5 min of ischemia to the first 5 min of reperfusion). LV-IS were 48.9 ± 8.9%, 41.5 ± 5.4%, 25.8 ± 7.7% and 16.8 ± 7.3% for saline, esmolol, milrinone, and esmolol + milrinone, respectively (n = 12/group). Esmolol + milrinone further reduced LV-IS compared with esmolol or milrinone alone (p < 0.05). LV-IS-reduction induced by esmolol + milrinone was eliminated in the presence of protein kinase A-(PKA)-inhibitor (Rp-cAMPS) or Akt-inhibitor (AKT 1/2 kinase inhibitor). In mixed rat ventricular cardiomyocyte cultures, intra-ischemic application of esmolol, milrinone or esmolol + milrinone reduced myocyte death rates by 5.5%, 13.3%, and 16.8%, respectively, compared with saline (p < 0.01). This cell protective effect by esmolol + milrinone was abrogated in the presence of PKA-inhibitor or Akt-inhibitor. Esmolol, milrinone or esmolol + milrinone increased myocardial PKA activity by 22%, 28% and 59%, respectively, compared with saline (n = 6, p < 0.01). No non-specific adverse effect of Rp-cAMPS on myocytes was identified in a purified myocyte preparation during hypoxia/re-oxygenation. Antiapoptotic pathways were assessed by measuring myocardial phosphorylated Akt (pAkt) levels combined with terminal dUTP nick-end labelling staining analysis. Ten minutes following infusion of esmolol, milrinone or esmolol + milrinone, there were 1.7-, 2.7-, and 6-fold increase in tissue pAkt levels, respectively. This esmolol + milrinone induced pAkt activation was abolished in the presence of PKA inhibitor. Esmolol, milrinone and esmolol + milrinone reduced myocyte apoptosis rates by 22%, 37% and 60%, respectively, compared with saline (p < 0.01).
Conclusions: Late-ischemia/early reperfusion therapy with esmolol + milrinone additively reduces LV-IS associated with robust activation of myocardial PKA and subsequent Akt-antiapoptotic pathway.
Conflict of interest statement
No potential interest conflicts.
Figures
References
- Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway (review) Cardiovasc Res. 2004;61:448–60. doi: 10.1016/j.cardiores.2003.09.024.
- Ovitz M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy D, et al. Postconditioning and protection from reperfusion injury: where do we stand? Cardiovasc Res (Review) 2010;87:406–23. doi: 10.1093/cvr/cvq129.
- Skyschally A, Gaster PV, Boengler K, Gres P, Musiolik J, Schilawa D, Schulz R, Heusch G. Ischemic postconditioning in pigs no causal role for RISK activation. Circ Res. 2009;104:15–8. doi: 10.1161/CIRCRESAHA.108.186429.
- Huang MH, Friend DS, Sunday ME, Singh K, Haley K, Austen KF, et al. An intrinsic adrenergic system in mammalian heart. J Clin Invest. 1996;98:1298–303. doi: 10.1172/JCI118916.
- Huang MH, Wang HQ, Roeske WR, Birnbaum Y, Wu Y, Yang NP, et al. Mediating δ-opioid-initiated heart protection via the β2-adrenergic receptor: role of the intrinsic cardiac adrenergic cell. Am J Physiol Heart Circ Physiol. 2007;293:H376–84. doi: 10.1152/ajpheart.01195.2006.
- Huang MH, Nguyen V, Wu Y, Rastogi S, Birnbaum Y, Lui CY, et al. Reducing ischemia/reperfusion injury through δ-opioid-regulated intrinsic cardiac adrenergic cells: adrenopeptidergic co-signaling. Cardiovasc Res. 2009;84:452–60. doi: 10.1093/cvr/cvp233.
- Aiyar N, Rand K, Elshourbagy NA, Zeng Z, Adamou JE, Bergsma DJ, et al. A cDNA encoding the calcitonin gene-related peptide type 1 receptor. J Biol Chem. 1996;271:11325–9. doi: 10.1074/jbc.271.19.11325.
- Huang MH, Knight PR, III, Izzo JL. Ca2+-dependent Ca2+-mobilization involved in CGRP-mediated positive inotropic effect in ventricular myocytes. Am J Physiol Regul Integr Comp Physiol. 1999;276:R259–64.
- Tong H, Bernstein ME, Steenbergen C. The role of beta-adrenergic receptor signaling in cardioprotection. FASEB J. 2005;19:983–5.
- Huang MH, Nguyen V, Rastogi S, Wu Y, Birnbaum Y, Lin Y, et al. Post-ischemic therapy with calcitonin gene-related peptide and β2-adrenergic receptor agonist confers synergistic infarct size reduction. Circ Res. (abstract) 2007;101:1210.
- Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of β1- and β2-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation. 1999;100:2210–2.
- Zhu WZ, Zheng M, Koch WJ, Lefkowitz RJ, Kobilka BK, Xiao RP. Dual modulation of cell survival and cell death by β2-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci USA. 2001;98:1607–12. doi: 10.1073/pnas.98.4.1607.
- Haikala H, Kaheinen P, Levijoki, Linden IB. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of new calcium sensitizer Levosimendan. Cardiovasc Res. 1997;34:536–46.
- Sanada S, Kitakaze M, Papst PJ, Asanuma H, Node K, Takashima S, et al. Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitor: the role of protein kinases A and p38 mitogen-activated protein kinase. Circulation. 2001;104:705–10. doi: 10.1161/hc3201.092216.
- Geissler HJ. Reduction of myocardial reperfusion injury by high-dose beta-blocker with esmolol. Thorac Cardiovasc Surg. 2002;50:367–72. doi: 10.1055/s-2002-35730.
- Killingsworth CR, Wei C-C, Dell’Italia LJ, Ardell JL, Kingsley MA, Smith WM, Ideker RE, Walcott GP. Short-acting β-adrenergic antagonist esmolol given at reperfusion improves survival after prolonged ventricular fibrillation. Circulation. 2004;109:2469–2474. doi: 10.1161/01.CIR.0000128040.43933.D3.
- Hein M, Roehl AB, Baumert JH, Scherer K, Steendijk P, Rossaint R. Anti-ischemic effects of inotropic agents in experimental right ventricular infarction. Acta Anaesthesiol Scand. 2009;53:941–8. doi: 10.1111/j.1399-6576.2009.01994.x.
- Wu Y, Yin X, Wijaya C, Huang M, McConnell BK. Acute myocardial infarction in rats. JoVE. 2011, 48: . doi: 10.3791/2464.
- Katzberg AA, Farmer BB, Harris RA. The predominance of binucleation in isolated rat heart myocytes. Am J Anat. 2005;149:489–99. doi: 10.1002/aja.1001490406.
- Campbell CA, Reddy BR, Alker KJ, Wynne J, Kloner RA. Effect of milrinone on acute myocardial infarct size. Am J Cardiol. 1987;60:422–3. doi: 10.1016/0002-9149(87)90276-1.
- Fukasawa M, Nishida H, Sato T, Miyazaki M, Nakaya H. 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2-(1H)quinolinone (cilostazol), a phosphodiesterase type 3 inhibitor, reduces infarct size via activation of mitochondrial Ca2+-activated K+ channels in rabbit hearts. J Pharmacol Exp Ther. 2008;326:100–4. doi: 10.1124/jpet.108.136218.
- Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359:473–81. doi: 10.1056/NEJMoa071142.
- Morisco C, Condorelli G, Trimarco V, Bellis A, Marrone C, Sadoshima J, et al. Akt mediates the cross-talk between beta-adrenergic and insulin receptors in neonatal cardiomyocytes. Circ Res. 2005;96:180–8. doi: 10.1161/01.RES.0000152968.71868.c3.
- Halkin A, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE, et al. Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. J Am Coll Cardiol. 2004;43:1780–7. doi: 10.1016/j.jacc.2003.10.068.
- Pedersen TR. The Norwegian multicenter study of timolol after myocardial infarction. Circulation. 1983;67:I49–53.
- Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339:489–97. doi: 10.1056/NEJM199808203390801.
- Karlsberg RP, DeWood MA, DeMaria AN, Berk MR, Lasher KP. Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Milrinone-Dobutamine Study Group. Clin Cardiol. 1996;19:21–30. doi: 10.1002/clc.4960190106.
- Mooss AN, Hilleman DE, Mohiuddin SM, Hunter CB. Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy. Ann Pharmacother. 1994;28:701–3.
Source: PubMed